CINECA IRIS Institutional Research Information System

ORLANDI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.423
AS - Asia 2.748
EU - Europa 2.747
SA - Sud America 388
AF - Africa 145
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 13.462
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.269
SG - Singapore 937
IT - Italia 878
CN - Cina 802
HK - Hong Kong 470
DE - Germania 461
SE - Svezia 435
BR - Brasile 334
BG - Bulgaria 188
GB - Regno Unito 185
VN - Vietnam 141
FI - Finlandia 127
CA - Canada 119
TR - Turchia 98
FR - Francia 86
RU - Federazione Russa 82
IN - India 76
UA - Ucraina 71
CI - Costa d'Avorio 67
AT - Austria 59
JP - Giappone 39
KR - Corea 35
PL - Polonia 29
BE - Belgio 27
CH - Svizzera 26
NG - Nigeria 25
BD - Bangladesh 24
NL - Olanda 20
SN - Senegal 18
AR - Argentina 16
MX - Messico 16
ID - Indonesia 14
PK - Pakistan 14
IQ - Iraq 13
SA - Arabia Saudita 12
CZ - Repubblica Ceca 11
EC - Ecuador 11
CO - Colombia 10
ES - Italia 10
MA - Marocco 10
UZ - Uzbekistan 10
ZA - Sudafrica 10
PH - Filippine 9
VE - Venezuela 9
AU - Australia 8
DK - Danimarca 8
LT - Lituania 8
IR - Iran 7
GR - Grecia 5
IE - Irlanda 5
JO - Giordania 5
TW - Taiwan 5
CR - Costa Rica 4
HU - Ungheria 4
NO - Norvegia 4
PS - Palestinian Territory 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
AZ - Azerbaigian 3
BB - Barbados 3
BJ - Benin 3
DO - Repubblica Dominicana 3
EG - Egitto 3
JM - Giamaica 3
LB - Libano 3
NP - Nepal 3
PY - Paraguay 3
RO - Romania 3
RS - Serbia 3
TT - Trinidad e Tobago 3
AM - Armenia 2
BH - Bahrain 2
CL - Cile 2
HR - Croazia 2
IL - Israele 2
KE - Kenya 2
MD - Moldavia 2
MY - Malesia 2
OM - Oman 2
PE - Perù 2
PT - Portogallo 2
TH - Thailandia 2
A1 - Anonimo 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CY - Cipro 1
DZ - Algeria 1
EE - Estonia 1
EU - Europa 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
GS - Georgia del Sud e Isole Sandwich Australi 1
HN - Honduras 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 13.457
Salva come PNG Salva come JPEG
Città #
Woodbridge 833
Ashburn 772
Fairfield 612
Ann Arbor 603
Singapore 508
Hong Kong 466
Dallas 464
Houston 460
Chandler 458
Santa Clara 420
Seattle 304
Wilmington 255
Cambridge 231
Serra 218
Shanghai 192
Sofia 187
Beijing 174
New York 148
Milan 143
Los Angeles 116
Boardman 114
Munich 102
Ottawa 85
Princeton 84
Lawrence 75
Medford 69
Abidjan 67
Jacksonville 62
Dong Ket 60
Des Moines 59
London 54
Dearborn 53
Pisa 51
Izmir 50
Florence 49
Vienna 49
Turku 46
Hefei 44
Frankfurt am Main 42
Buffalo 38
Nanjing 38
Rome 37
Istanbul 35
Tokyo 33
Seoul 32
Ogden 31
São Paulo 31
Redondo Beach 30
Boulder 29
Brussels 27
Columbus 27
Düsseldorf 27
San Diego 27
The Dalles 27
Falls Church 24
Fuzhou 24
Lagos 24
Bremen 23
Helsinki 23
Nanchang 23
Ho Chi Minh City 21
Warsaw 21
Bern 20
Marseille 19
San Jose 19
Dakar 18
Lucca 18
Redwood City 18
Council Bluffs 17
Pune 16
Nürnberg 14
Phoenix 13
Quanzhou 13
Shenyang 13
Stockholm 13
Hanoi 12
Lancaster 12
Montreal 12
Rho 12
Boston 11
Denver 11
Hebei 11
Kunming 11
Norwalk 11
Vicopisano 11
Jüchen 10
Nuremberg 10
Seacroft 10
Toronto 10
Guangzhou 9
Rio de Janeiro 9
Auburn Hills 8
Belo Horizonte 8
Tashkent 8
Atlanta 7
Brooklyn 7
Dülmen 7
Hangzhou 7
Jiaxing 7
Mumbai 7
Totale 9.880
Salva come PNG Salva come JPEG
Nome #
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions 383
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 278
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy 254
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. 245
VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 239
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 233
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 229
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 224
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 223
Gender, MGMT methylation, and levetiracetam plasma levels correlate with survival benefit in glioblastoma patients treated with adjuvant temozolomide: results from a non-interventional retrospective clinical study 220
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients 219
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study 215
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 213
Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy 213
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 209
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients 204
The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. 191
Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. 191
Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo 190
Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies. 189
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 185
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2 183
Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy 182
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 178
Low-dose metronomic cyclophosphamide plus celecoxib and dexamethasone in advanced hormone refractory prostate cancer (HRPC): a phase II clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination 166
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 164
Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation 163
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 161
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells 160
Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib ( C ) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): preliminary clinical and pharmacodynamic results 157
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. 157
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 156
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 155
In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists 153
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 151
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib 150
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells 145
Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer 144
Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). 142
Genetic interaction analysis of VEGF-A rs3025039 and VEGFR-2 rs2071559 identifies a genetic profile at higher risk to develop nodular goiter 140
Irinotecan Metronomic Chemotherapy (MC) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation 139
In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma 139
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer 139
Prevention of capecitabine toxicity using a 5-FU test dose 138
Overexpression and functional relevance of somatostatin receptor-1, -2, and -5 in endometrium and endometriotic lesions 137
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells 136
Polymorphisms interaction to predict bevacizumab (BV) efficacy in metastatic breast cancer (MBC) patients: an exploratory retrospective analysis. 135
IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 135
Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma 135
A new biometric tool for three-dimensional subcutaneous tumor scanning in mice. 132
Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation. Final report 131
Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1 131
Pilot study of correlation between single nucleotide polymorphisms (SNPS) of pro-and anti-angiogenic genes and response to bevacizumab (BV) plus chemotherapy (CT) in patients with metastatic breast cancer (MBC) 130
Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib 128
null 127
Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors 127
Old and New Systemic Immune-Inflammation Indexes Are Associated with Overall Survival of Glioblastoma Patients Treated with Radio-Chemotherapy 126
Agenti melanocortinici per l’impiego nel trattamento terapeutico del melanoma, dei tumori del tratto gastroenterico e del carcinoma tiroideo 126
Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer 125
Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical and pharmacodynamic evaluation 122
Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial. 118
Synergistic activity of linifanib and irinotecan increases the survival of mice bearing orthotopically implanted human anaplastic thyroid cancer 118
Polymorphisms interaction to predict bevacizumab (BV) efficacy in metastatic breast cancer (MBC) patients (pts): An exploratory retrospective analysis. 115
MELANOCORTIN AGENTS FOR USE IN THE THERAPEUTIC TREATMENT OF MELANOMA, TUMORS OF THE GASTROINTESTINAL TRACT, AND THYROID CARCINOMA 115
null 114
Vascular endothelial growth factor-A (VEGF-A) single nucleotide polymorphisms and endometriosis: still a controversial issue 114
null 114
Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer 113
Idarubicin and idarubicinol effects on breast cancer multicellular spheroids 112
Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells 112
Gender, MGMT methylation, and levetiracetam plasma levels correlate with survival benefit in glioblastoma patients treated with adjuvant temozolomide: results from a non-interventional retrospective clinical study 110
Antiangiogenic drugs in NASH: Evidence of a possible new therapeutic approach 110
Phase II clinical trial with pharmacodynamic evaluation of docetaxel/prednisone plus metronomic cyclophosphamide and celecoxib as first line treatment in metastatic hormone refractory prostate cancer (MHRPC) 103
All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma 103
Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma 102
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients 101
null 101
Polimorfismi genetici del VEGF e DMLE 97
Preclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer 97
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients 97
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 96
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients 96
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. 96
Discovery of a Potent Dual Inhibitor of Aromatase and Aldosterone Synthase 92
Predictive Power of Tissue and Circulating Biomarkers for the Severity of Biopsy-Validated Chronic Liver Diseases 89
null 89
Correction to: Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy 87
Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward 78
null 76
Metronomic Chemotherapy in Elderly Patients 75
Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-fluorouracil Antitumor Activity In Vitro and In Vivo 63
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer 57
null 46
GABAergic signaling in colorectal cancer: Mechanistic insights, tumor microenvironment crosstalk, and therapeutic opportunities 27
Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cells 27
Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathway 24
Melanocortin-4 Receptor Antagonism Inhibits Colorectal and Anaplastic Thyroid Cancer In Vitro and In Vivo 22
Synergistic activity of tafasitamab and metronomic chemotherapy on diffuse large B-cell lymphoma through inhibition of the AKT/mTOR signaling pathway 16
Totale 13.714
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.108
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.108
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021472 0 0 0 0 0 0 30 92 96 82 51 121
2021/2022917 14 71 21 32 154 154 26 34 53 40 54 264
2022/20231.467 175 223 126 128 158 187 9 104 259 6 80 12
2023/2024850 82 97 93 56 101 167 26 48 18 22 53 87
2024/20252.993 17 114 43 192 302 325 228 126 302 390 331 623
2025/20262.216 285 410 503 335 412 269 2 0 0 0 0 0
Totale 13.714